Joe Biden COVID-19 antiviral
President Joe Biden [Image courtesy of the White House]

President Biden said in his State of the Union address that the U.S. aims to ramp up the use of Pfizer‘s (NYSE:PFE) Plaxovid.

The treatment has been in short supply since it won emergency use authorization late last year.

Last year, when Merck & Co. (NYSE: MRK) and Pfizer were close to winning regulatory authorization for COVID-19 antivirals, many pundits hailed the treatments as a potential gamechanger.

To date, however, the use of antivirals has been limited, although demand has been especially high for Pfizer’s Paxlovid antiviral.

Get the full story from our sister site, Pharmaceutical Processing World